Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Uliledlimab · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Non-squamous Squamous |
| Group B | EXPERIMENTAL | Non-squamous Squamous |
| Group C | SHAM_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Uliledlimab | DRUG | 30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles |
| Sintilimab | DRUG | Intravenous infusion at a recommended dose of 200 mg once every 3 weeks，at most 35 cycles |
| Pemetrexed | DRUG | Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses. |
| Gemcitabine | DRUG | 1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles |
| Cisplatin Or Carboplatin | DRUG | Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles |
| Toripalimab | DRUG | 240 mg on Day 1, once every 3 weeks (Q3W) |
| Pembrolizumab | DRUG | 200 mg on Day 1, once every 3 weeks (Q3W) |
Inclusion Criteria: 1. Patients aged ≥ 18 years at the time of signing the ICF. 2. Patients with histologically or cytologically confirmed stage IIIB, IIIC, or IV NSCLC who are not suitable for radical surgery and/or radiotherapy. 3. Patients who have not received prior systemic therapy for their l...
Top 20 of 84 competitors
Uliledlimab is an investigational small molecule being studied for the treatment of Non Small Cell Lung Cancer (NSCLC). It is currently in Phase 2 clinical trials for patients with previously untreated locally advanced unresectable or metastatic disease, including those selected for PD-L1 and CD73 expression.
Uliledlimab targets CD73, an enzyme involved in adenosine production that can suppress immune responses in tumors. By inhibiting CD73, the drug aims to enhance the anti-tumor activity of the immune system, particularly when combined with checkpoint inhibitors like toripalimab or sintilimab.
Uliledlimab is being developed by I-Mab, a biopharmaceutical company listed as I-Mab Sponsored ADR under the ticker NBP. The company is conducting Phase 2 clinical trials for this drug in Non Small Cell Lung Cancer.
Uliledlimab is in Phase 2 clinical development. It is not yet approved by regulatory authorities and remains an investigational drug. Two Phase 2 trials are currently active but not recruiting patients, with a combined planned enrollment of 600 participants.
Uliledlimab is being evaluated in two Phase 2 trials. NCT06984588 compares Uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in 450 patients with PD-L1- and CD73-selected NSCLC. NCT07005336 compares Uliledlimab combined with sintilimab and chemotherapy versus sintilimab and chemotherapy in 150 patients.
No, Uliledlimab is a distinct investigational drug with no alternative names listed. It is being studied as a monotherapy and in combination with other agents, but it is not known to be identical to any other approved or investigational medication.